跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

415M-1

Sigma-Aldrich

EZH2 (11) Mouse Monoclonal Antibody

登录查看公司和协议定价


About This Item

UNSPSC代码:
12352203
NACRES:
NA.41

生物来源

mouse

质量水平

100
500

偶联物

unconjugated

抗体形式

culture supernatant

抗体产品类型

primary antibodies

克隆

11, monoclonal

描述

For In Vitro Diagnostic Use in Select Regions (See Chart)

形式

buffered aqueous solution

种属反应性

human

包装

vial of 0.1 mL concentrate (415M-14)
vial of 0.5 mL concentrate (415M-15)
bottle of 1.0 mL predilute (415M-17)
vial of 1.0 mL concentrate (415M-16)
bottle of 7.0 mL predilute (415M-18)

制造商/商品名称

Cell Marque

技术

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100

同位素/亚型

IgG1

控制

breast carcinoma, prostate adenocarcinoma, tonsil

运输

wet ice

储存温度

2-8°C

可视化

nuclear

基因信息

human ... EZH2(2146)

一般描述

Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2). It generates a methylation epigenetic mark at lysine 27 residue of histone H3 (H3K27me3) in order to silence gene expression. EZH2 target genes are involved in a variety of biological processes such as stem cell pluripotency, cell proliferation, and oncogenic transformation. EZH2 is frequently overexpressed in many cancer types. Hyperactivation of EZH2, either by overexpression or muta­tions, is found in a variety of malignancies including prostate, breast, uterine, gastric, and renal cell cancers in addition to melanoma. EZH2 overexpression has been reported in non-small cell lung cancers and lymphoma.The EZH2 protein is rarely detected in normal breast duct epithelium and in normal and hyperplastic lymph node. EZH2 is usually expressed in follicular centers, but not in mantle zones, follicular and interfollicular T cells, plasma cells or NK/T cells. However, its expression can be seen in most B-cell and T-cell lymphomas, although only in 20% (1/5) of small lymphocytic lymphoma and 14% (1/7) of plasma cell myeloma. Plasmacytoma, lymphoplasmacytic lymphoma, and MALT lymphoma have not been shown to express this protein. Recent studies also have demonstrated EZH2 is aberrantly over-expressed in pediatric rhabdomyosarcoma, independent of the histological subtypes. In summary, EZH2 correlates with tumor proliferation and may be used in an antibody panel to differentiate proliferative/aggressive lymphoma variants from indolent ones and normal resting cell populations

质量


IVD

IVD

IVD

RUO

联系

EZH2 Positive Control Slides, Product No. 415S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

外形

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

制备说明

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

其他说明

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

法律信息

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our 产品选型工具.

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Lamia Abd Al Kader et al.
Virchows Archiv : an international journal of pathology, 463(5), 697-711 (2013-08-21)
Polycomb group (PcG) proteins are important for the regulation of hematopoiesis by regulating chromatin compaction and silencing genes related to differentiation and cell cycle. Overexpression of enhancer of zeste homologue 2 (Ezh2) and Bmi-1/PCGF4 has been implicated in solid organ
Jin-zhi Tan et al.
Acta pharmacologica Sinica, 35(2), 161-174 (2013-12-24)
EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which is a highly conserved histone methyltransferase that methylates lysine 27 of histone 3. Overexpression of EZH2 has been found in a wide range of cancers, including those
Roberta Ciarapica et al.
BMC medicine, 9, 63-63 (2011-05-26)
Soft tissue sarcomas of childhood are a group of heterogeneous tumors thought to be derived from mesenchymal stem cells. Surgical resection is effective only in about 50% of cases and resistance to conventional chemotherapy is often responsible for treatment failure.
Sooryanarayana Varambally et al.
Nature, 419(6907), 624-629 (2002-10-11)
Prostate cancer is a leading cause of cancer-related death in males and is second only to lung cancer. Although effective surgical and radiation treatments exist for clinically localized prostate cancer, metastatic prostate cancer remains essentially incurable. Here we show, through

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门